Target intelligence / Profile preview

Tumor antigen presentation via major histocompatibility complex class I and II pathway (MHC class I/II antigen presentation pathway)

Target
MHC class I/II antigen presentation pathway
Molecular classification
Receptor (for MHC molecules themselves), Protein complex (for APM components), Transporter (e.g., TAP transporter in MHC-I pathway)
01

Overview

The major histocompatibility complex (MHC) class I and II pathways are central mechanisms by which cells present antigens—including those derived from intracellular pathogens or mutated proteins—to immune effector cells. The process involves several steps: generation and trimming of peptides from cellular proteins by proteasomes (especially immunoproteasomes for optimal epitope generation), transport into the endoplasmic reticulum by specialized transporters like TAP for MHC-I peptides, loading onto nascent MHC molecules with assistance from chaperones such as tapasin and calnexin/carletriculin complexes, followed by surface expression where they can be recognized by CD8+ cytotoxic T lymphocytes. For exogenous antigens taken up through endocytosis/phagocytosis—such as those from extracellular bacteria—antigens are processed within endosomes before being loaded onto newly synthesized MHC-II molecules with help from invariant chain removal facilitated by HLA-DO/DM chaperones. The resulting complexes then migrate to the plasma membrane where they activate CD4+ helper T lymphocytes.[1][2][3] Defects in these pathways allow cancers to evade immune detection but also provide opportunities for therapeutic intervention aimed at restoring proper function so that tumors become visible again to host immunity.[1]

Other names
Major histocompatibility complex class I and II antigen processing and presentation machineryMHC-I/MHC-II APMHLA (human leukocyte antigen) class I/II pathway (in humans)Antigen processing and presenting machinery (APM)
02

Mechanism of action

Enhancement of tumor-specific peptide-MHC expression on cancer cells; restoration of defective APM function; stimulation of CD8+ cytotoxic T cell responses via improved endogenous peptide-MHC-I display; stimulation of CD4+ helper T cell responses via exogenous peptide-MHC-II display. Note: Direct modulation is rare. Most strategies aim to restore or enhance natural function rather than inhibit it.

03

Biological functions

Immune responseAntigen processingAntigen presentation to T cellsImmune surveillance against tumors and pathogens
04

Disease associations

Cancer immune evasionTumor progressionInfection susceptibility
05

Safety considerations

Autoimmunity due to enhanced self-antigen presentation if therapy is too broadlack of efficacy if tumor has lost essential components required for effective antigen processing/presentation. Note: Loss-of-function mutations/deletions in APM genes can render immunotherapies ineffective.
06

Interacting drugs

Checkpoint inhibitors targeting T cell activation downstream of MHC-antigen recognition (e.g., anti-PD-1/PD-L1 antibodies such as pembrolizumab or nivolumab; these do not directly interact with the MHC or APM but depend on its function)

2 more in the full profile.

07

Biomarkers

Expression levels of MHC class I/II molecules on tumor cellspresence or absence of key APM components such as β2-microglobulin, LMP2/LMP7/TAP transporters in tumorsneoantigen load in tumors. Note: These biomarkers are used for patient selection in immunotherapy trials and monitoring efficacy.

Beyond the preview

Go deeper on Tumor antigen presentation via major histocompatibility complex class I and II pathway (MHC class I/II antigen presentation pathway).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor antigen presentation via major histocompatibility complex class I and II pathway (MHC class I/II antigen presentation pathway).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call